Ruf Andrés E, Villamil Federico G
Unidad de hepatología, cirugía hepatobiliar y trasplante hepático, Fundación Favaloro.
Acta Gastroenterol Latinoam. 2008 Mar;38(1):75-88.
Liver transplantation (OLT) is indicated in patients with severe and irreversible acute or chronic liver disease without alternative therapy and in the absence of contraindications. Indications for OLT can be grouped in four categories, namely cirrhosis, fulminant hepatitis, malignant hepatic tumors and liver-based genetic defects that trigger damage of other organs. Patients with cirrhosis should be referred for OLT after the onset of any of the major complications or coagulopathy. Early referral is crucial in fulminant hepatitis due to the high mortality with medical therapy and the unpredictable nature of this condition. Ideal timing for OLT is the moment in the natural history of the disease when the expected survival of patients on the waiting list is higher with than without OLT. Recent data suggest that maximal benefit of OLT is obtained in patients with a MELD score >15. However, in some cases with no imminent risk of death, OLT is indicated to improve quality of life or to prevent contraindications such as progression of hepatocellular carcinoma. At present, there is a marked disproportion between the number of donors available and the growing number of patients listed worldwide, which in turn has resulted in prolongation of the time-interval to OLT and waitlist mortality. The rationale of allocation systems utilizing the MELD score is to prioritize on the waiting list patients with severe liver dysfunction ("the sickest first") and those with hepatocellular carcinoma who may loose the benefits of OLT when waitlist time exceeds eight months.
肝移植(OLT)适用于患有严重且不可逆的急性或慢性肝病、无替代治疗方法且无禁忌症的患者。OLT的适应症可分为四类,即肝硬化、暴发性肝炎、肝脏恶性肿瘤以及引发其他器官损害的肝脏基因缺陷。肝硬化患者在出现任何主要并发症或凝血障碍后应转诊进行OLT。对于暴发性肝炎,早期转诊至关重要,因为药物治疗死亡率高且病情不可预测。OLT的理想时机是在疾病自然史中,等待名单上的患者接受OLT比不接受OLT预期生存率更高的时刻。近期数据表明,终末期肝病模型(MELD)评分>15的患者接受OLT获益最大。然而,在一些没有即刻死亡风险的情况下,进行OLT是为了改善生活质量或预防诸如肝细胞癌进展等禁忌症。目前,全球可用供体数量与登记患者数量的增长之间存在明显失衡,这反过来导致了OLT时间间隔延长和等待名单上的患者死亡率上升。利用MELD评分的分配系统的基本原理是在等待名单上优先考虑肝功能严重受损的患者(“病情最重者优先”)以及那些等待名单时间超过八个月可能会失去OLT益处的肝细胞癌患者。